相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Marinella Clerico et al.
NEUROTHERAPEUTICS (2020)
Pharmacodynamics of natalizumab extended interval dosing in MS
Lana Zhovtis Ryerson et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab
Eleonora Sgarlata et al.
CNS DRUGS (2020)
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
Cristina Scarpazza et al.
NEUROLOGICAL SCIENCES (2019)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Nicholas Schwab et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Nicholas Schwab et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Maria Trojano et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Efficacy and safety of natalizumab extended interval dosing
Bassem Yamout et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Cladribine Tablets: A Review in Relapsing MS
Emma D. Deeks
CNS DRUGS (2018)
Multiple Sclerosis: Immunopathology and Treatment Update
Narges Dargahi et al.
BRAIN SCIENCES (2017)
High cumulative JC virus seroconversion rate during long-term use of natalizumab
A. Vennegoor et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Extended interval dosing of natalizumab in multiple sclerosis
L. Zhovtis Ryerson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
Luca Prosperini et al.
PLOS ONE (2016)
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
Tim Spelman et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
Barbara H. Johnson et al.
CNS DRUGS (2015)
Body weight-based natalizumab treatment in adult patients with multiple sclerosis
M. Tanaka et al.
JOURNAL OF NEUROLOGY (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis
Luca Prosperini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
P. Wipfler et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort
O. Outteryck et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Extended interval dosing of natalizumab: a two-center, 7-year experience
Roberto Bomprezzi et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
R. Lanzillo et al.
NEUROLOGICAL SCIENCES (2013)
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped
Theo Rispens et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis
Luigi M. E. Grimaldi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study
Oscar Fernandez et al.
MULTIPLE SCLEROSIS (2011)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri (R)) in inflammatory diseases
Olaf Stueve et al.
CNS DRUG REVIEWS (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
An open-label safety and drug interaction study of natalizumab (Antegren (TM)) in combination with interferon-beta (Avonex (R)) in patients with multiple sclerosis
TL Vollmer et al.
MULTIPLE SCLEROSIS JOURNAL (2004)
分享论文
